Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:25 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)
NCT00677521 · The Hospital for Sick Children · PHASE2 · terminated · last registry update 2013-08-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “poor recruitment and no student currently interested in working on this project.” | – | Registry record, The Hospital for Sick Children |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AMY2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2014-04-28Results posted on the registry: Merck Sharp & Dohme LLC, Sitagliptin phosphate + Comparator: Placebo (NCT01177384)
- 2013-05-01Results posted on the registry: Yale University, Acarbose (NCT00846521)
- 2013-05-01Also stopped (terminated): Yale University, Acarbose (NCT00846521)
- 2012-10-19Results posted on the registry: Novartis Pharmaceuticals, Nateglinide + Acarbose (NCT01030952)
- 2012-10-02Phase 3 first posted: Merck Sharp & Dohme LLC, Omarigliptin + Matching placebo to omarigliptin (NCT01697592)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision